27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
iBio Inc (NYSE:IBIO) received the FDA response to its pre-investigational new drug (IND) package for IBIO-202, the Company's lead COVID-19 vaccine program.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
- In light of the feedback received, the Company is moving forward with IND-enabling challenge studies for its second-generation vaccine candidate targeting the nucleocapsid (N) protein.
- It plans to file an IND application before the end of calendar 2022.
- The Company previously reported completing extensive preclinical studies and identifying an antigen-adjuvant pairing with a favorable Th1 skew.
- The cytokine response observed with this pairing indicated a primary immune response, differentiation of mature T cells, and reactivation of memory T-cells.
- In September 2021, iBio submitted a pre-IND package for IBIO-202 to the FDA.
- In November 2021, the Company entered a collaboration agreement with a provider of microarray patch systems to evaluate the feasibility of intradermal delivery of a COVID-19 vaccine antigen.
- Price Action: IBIO shares are down 1.29% at $0.47 during the market session on the last check Wednesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.